The association of CYP2D6 *10 polymorphism with breast cancer risk and clinico-pathologic characteristics in Chinese women

References

• Gao YT, Shu XO, Dai Q, Potter JD, Brinton LA, Wen W, et al. Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer 2000; 87: 295–300
   PubMed Web of Science ®Google Scholar
• Nathanson KL, Wooster R, Weber BL. Breast cancer genetics: what we know and what we need. Nat Med 2001; 7: 552–6
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ, Gelboin HV. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 1994; 26: 165–83
   PubMed Web of Science ®Google Scholar
• Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8: 843–54
   PubMed Web of Science ®Google Scholar
• Pontin JE, Hamed H, Fentiman IS, Idle JR. Cytochrome P450dbl phenotypes in malignant and benign breast disease. Eur J Cancer 1990; 26: 790–2
   PubMed Web of Science ®Google Scholar
• Ladero JM, Benitez J, Jara C, Llerena A, Valdivielso MJ, Munoz JJ, et al. Polymorphic oxidation of debrisoquine in women with breast cancer. Oncology 1991; 48: 107–10
   PubMed Web of Science ®Google Scholar
• Huober J, Bertram B, Petru E, Kaufmann M, Schmahl D. Metabolism of debrisoquine and susceptibility to breast cancer. Breast Cancer Res Treat 1991; 18: 43–8
   PubMed Web of Science ®Google Scholar
• Ladona MG, Abildua RE, Ladero JM, Roman JM, Plaza MA, Agundez JA, et al. CYP2D6 genotypes in Spanish women with breast cancer. Cancer Lett 1996; 99: 23–8
   PubMed Web of Science ®Google Scholar
• Topic E, Stefanovic M, Ivanisevic AM, Petrinovic R, Curcic I. The cytochrome P450 2D6 (CYP2D6) gene polymorphism among breast and head and neck cancer patients. Clin Chim Acta 2000; 296: 101–9
   PubMed Web of Science ®Google Scholar
• Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284–95
   PubMed Web of Science ®Google Scholar
• Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 2000; 46: 1072–7
   PubMed Web of Science ®Google Scholar
• Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7: 193–202
   PubMedGoogle Scholar
• Ji L, Pan S, Marti-Jaun J, Hanseler E, Rentsch K, Hersberger M. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin Chem 2002; 48: 983–8
   PubMed Web of Science ®Google Scholar
• Garcia-Barcelo M, Chow LY, Chiu HF, Wing YK, Lee DT, Lam KL, et al. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem 2000; 46: 18–23
   PubMed Web of Science ®Google Scholar
• Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452–9
   PubMed Web of Science ®Google Scholar
• Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993; 53: 410–8
   PubMed Web of Science ®Google Scholar
• Nilsson G, Skytting B, Xie Y, Brodin B, Perfekt R, Mandahl N, et al. The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome. Cancer Res 1999; 59: 3180–4
   PubMed Web of Science ®Google Scholar
• Agundez JA, Martinez C, Ladero JM, Ledesma MC, Ramos JM, Martin R, et al. Debrisoquin oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther 1994; 55: 10–4
   PubMed Web of Science ®Google Scholar
• Agundez JA, Ledesma MC, Benitez J, Ladero JM, Rodriguez-Lescure A, Diaz-Rubio E, et al. CYP2D6 genes and risk of liver cancer. Lancet 1995; 345: 830–1
   PubMed Web of Science ®Google Scholar
• Wolf CR, Smith CA, Gough AC, Moss JE, Vallis KA, Howard G, et al. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 1992; 13: 1035–8
   PubMed Web of Science ®Google Scholar
• Agundez JA. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab 2004; 5: 211–24
   PubMed Web of Science ®Google Scholar
• Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain G, et al. Breast carcinoma survival in Europe and the United States. Cancer 2004; 100: 715–22
   PubMed Web of Science ®Google Scholar
• Woo CS, Silberman H, Nakamura SK, Ye W, Sposto R, Colburn W, et al. Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer. Am J Surg 2002; 184: 337–40
   PubMed Web of Science ®Google Scholar
• Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95: 1758–64
   PubMed Web of Science ®Google Scholar
• El-Rayes BF, Ali S, Heilbrun LK, Lababidi S, Bouwman D, Visscher D, et al. Cytochrome p450 and glutathione transferase expression in human breast cancer. Clin Cancer Res 2003; 9: 1705–9
   PubMed Web of Science ®Google Scholar
• Modugno F, Knoll C, Kanbour-Shakir A, Romkes M. A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat 2003; 82: 191–7
   PubMed Web of Science ®Google Scholar